Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

How much apple cider vinegar reduces weight? Meta-analysis points to 30 mL daily

A new meta-analysis of randomized controlled trials shows apple cider vinegar can modestly but significantly reduce body weight, BMI, and waist circumference in adults, particularly those with obesity or type 2 diabetes.

22 Sep 2025

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists (dual agonists such tirzepatide).

21 Sep 2025

Study points to a surprising new ally in the fight against type 2 diabetes

A new study from Duke University School of Medicine is challenging long-standing views on blood sugar regulation - and pointing to a surprising new ally in the fight against type 2 diabetes.

19 Sep 2025

New study warns of millions of undiagnosed and missing people with type 1 diabetes

The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates, according to the results of a new modeling study being presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Vienna (15-19 Sept).

19 Sep 2025

Oral drug baricitinib shows promise in slowing early type 1 diabetes progression

In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial [1] reported that a daily pill of baricitinib, commonly prescribed for rheumatoid arthritis and alopecia, could safely preserve the body's own insulin production and slow the progression of type 1 diabetes (T1D) in people recently diagnosed with the condition.

19 Sep 2025

Can eating style affect how well GLP-1 drugs control diabetes and weight?

Research indicates that external eating behavior is a key predictor of weight loss in type 2 diabetes patients receiving GLP-1 receptor agonists.

19 Sep 2025

New findings support low-dose ATG to delay progression of type 1 diabetes

New research presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published simultaneously in The Lancet shows that a much lower dose than previously thought of the old immunomodulatory drug anti-thymocyte globulin (ATG) is safe and effective in preventing progression of type 1 diabetes (T1D) in young people.

19 Sep 2025

Verapamil shows potential for preserving beta-cell function in type 1 diabetes

New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil (360mg daily) could have a potential effect on beta-cell function in adults with newly diagnosed type 1 diabetes.

18 Sep 2025

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.

18 Sep 2025

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

18 Sep 2025

Evening meals hold the key to morning glucose control in prediabetes

The way glucose is regulated at night plays a key role in fasting glucose levels the next morning, when blood sugar is expected to be at its lowest.

18 Sep 2025

Mediterranean diet may protect gums by reducing severe periodontitis

This study reveals that the Mediterranean diet may protect against periodontitis, highlighting its benefits for oral health and inflammation reduction.

18 Sep 2025

Peroxisomes identified as alternative heat producers in brown fat

Researchers at Washington University School of Medicine in St. Louis have identified a novel way brown fat - an energy-burning form of fat - can rev the body's metabolic engine, consuming cellular fuel and producing heat in a way that improves metabolic health.

17 Sep 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

The mind-gut connection: How emotional eating affects GLP-1 drug success

GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes - helping stabilize blood glucose and lose weight which contributes to diabetes complications. But not everyone benefits equally.

17 Sep 2025

Lifestyle changes show promise in preventing cognitive decline and Alzheimer’s disease

An estimated 7.2 million Americans over age 65 currently live with Alzheimer's disease (AD). That number is expected to nearly double to 13.8 million by 2060.

16 Sep 2025

Younger adults and men with type 2 diabetes face higher risk of sepsis

Living with type 2 diabetes (T2D) may double the risk of developing sepsis-with those aged younger than 60 years and men particularly susceptible, according to a long-term community-based study in Australia, being presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Vienna (15-19 Sept).

16 Sep 2025

Gestational diabetes poses substantial cognitive dysfunction risks for both mothers and offspring

A new synthesis of global evidence finds that experiencing gestational diabetes during pregnancy is linked with a decline in intellectual function among mothers, and may increase the risk of neurodevelopmental disorders, including autism spectrum disorder and attention-deficit/hyperactivity disorder (ADHD) in children.

15 Sep 2025

Cannabis use may quadruple the risk of developing diabetes

Cannabis use is linked to an almost quadrupling in the risk of developing diabetes, according to an analysis of real-world data from over 4 million adults, being presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 Sept).

15 Sep 2025

Keto diet reduces depression symptoms by 70% in college students

Research indicates a ketogenic diet may serve as an effective adjunct therapy for major depression in college students, improving mood and cognitive abilities.

15 Sep 2025